BACKGROUND: Individual genome-wide linkage scans and meta-analyses support that one or more susceptibility genes for schizophrenia are located in chromosome 8p. A gene from this region, neuregulin 1 (NRG1 ), known to be involved with glutamatergic function, has been found to be associated in some studied samples. METHOD: We have examined a new combined schizophrenia sample with 136 schizophrenia families largely of European ancestry (EA) and 646 subjects with DNA. We genotyped 14 single nucleotide polymorphisms (SNPs) in NRG1 including those reported to comprise schizophrenia-associated haplotypes in Icelandic, Scottish, Irish, and Chinese Han populations. RESULTS: We found no evidence of association at a single-marker or a haplotypic level. We review methodological aspects of previous studies to enable us to put our findings into context. CONCLUSIONS: Our failure to find an association between NRG1 and schizophrenia might reflect different linkage disequilibrium (LD) patterns found in different populations, disease allelic heterogeneity, clinical heterogeneity of schizophrenia, or inadequate statistical power deriving from moderate sample size. NRG1, if a true gene for schizophrenia, accounts for a small fraction of the disease in most populations. The confirmation of NRG1 as a schizophrenia susceptibility gene will require studies with a comprehensive set of markers and in larger samples. The possibility remains that reports of NRG1 association might reflect false positives.
BACKGROUND: Individual genome-wide linkage scans and meta-analyses support that one or more susceptibility genes for schizophrenia are located in chromosome 8p. A gene from this region, neuregulin 1 (NRG1 ), known to be involved with glutamatergic function, has been found to be associated in some studied samples. METHOD: We have examined a new combined schizophrenia sample with 136 schizophrenia families largely of European ancestry (EA) and 646 subjects with DNA. We genotyped 14 single nucleotide polymorphisms (SNPs) in NRG1 including those reported to comprise schizophrenia-associated haplotypes in Icelandic, Scottish, Irish, and Chinese Han populations. RESULTS: We found no evidence of association at a single-marker or a haplotypic level. We review methodological aspects of previous studies to enable us to put our findings into context. CONCLUSIONS: Our failure to find an association between NRG1 and schizophrenia might reflect different linkage disequilibrium (LD) patterns found in different populations, disease allelic heterogeneity, clinical heterogeneity of schizophrenia, or inadequate statistical power deriving from moderate sample size. NRG1, if a true gene for schizophrenia, accounts for a small fraction of the disease in most populations. The confirmation of NRG1 as a schizophrenia susceptibility gene will require studies with a comprehensive set of markers and in larger samples. The possibility remains that reports of NRG1 association might reflect false positives.
Authors: Kristin K Nicodemus; Amanda J Law; Eugenia Radulescu; Augustin Luna; Bhaskar Kolachana; Radhakrishna Vakkalanka; Dan Rujescu; Ina Giegling; Richard E Straub; Kate McGee; Bert Gold; Michael Dean; Pierandrea Muglia; Joseph H Callicott; Hao-Yang Tan; Daniel R Weinberger Journal: Arch Gen Psychiatry Date: 2010-10
Authors: Falk W Lohoff; John P Dahl; Thomas N Ferraro; Steven E Arnold; Jürgen Gallinat; Thomas Sander; Wade H Berrettini Journal: Neuropsychopharmacology Date: 2006-08-23 Impact factor: 7.853
Authors: Jessica L Yokley; Konasale M Prasad; Kodavali V Chowdari; Michael E Talkowski; Joel Wood; Ruben C Gur; Raquel E Gur; Laura Almasy; Vishwajit L Nimgaonkar; Michael F Pogue-Geile Journal: Psychiatr Genet Date: 2012-04 Impact factor: 2.458
Authors: Brian K Suarez; Jubao Duan; Alan R Sanders; Anthony L Hinrichs; Carol H Jin; Cuiping Hou; Nancy G Buccola; Nancy Hale; Ann N Weilbaecher; Deborah A Nertney; Ann Olincy; Susan Green; Arthur W Schaffer; Christopher J Smith; Dominique E Hannah; John P Rice; Nancy J Cox; Maria Martinez; Bryan J Mowry; Farooq Amin; Jeremy M Silverman; Donald W Black; William F Byerley; Raymond R Crowe; Robert Freedman; C Robert Cloninger; Douglas F Levinson; Pablo V Gejman Journal: Am J Hum Genet Date: 2006-01-03 Impact factor: 11.025
Authors: Jubao Duan; Maria Martinez; Alan R Sanders; Cuiping Hou; Gregory J Burrell; Aaron J Krasner; Daniel B Schwartz; Pablo V Gejman Journal: Hum Hered Date: 2007-05-02 Impact factor: 0.444
Authors: H Magnus Haraldsson; Ulrich Ettinger; Brynja B Magnusdottir; Andres Ingason; Samuel B Hutton; Thordur Sigmundsson; Engilbert Sigurdsson; Hannes Petursson Journal: Eur Arch Psychiatry Clin Neurosci Date: 2009-07-03 Impact factor: 5.270
Authors: Fernando S Goes; Virginia L Willour; Peter P Zandi; Pamela L Belmonte; Dean F MacKinnon; Francis M Mondimore; Barbara Schweizer; Elliot S Gershon; Francis J McMahon; James B Potash Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2009-07-05 Impact factor: 3.568
Authors: L Elliot Hong; Ikwunga Wonodi; O Colin Stine; Braxton D Mitchell; Gunvant K Thaker Journal: Biol Psychiatry Date: 2007-07-12 Impact factor: 13.382